Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Turkey / NCT07828067
Starting soon Observational

Short Versus Standard Dental Implants: Clinical and Biomarker Outcomes

NCT07828067 · tracked via the Priya Life Science Turkey tracker
Sponsor
Inonu University
Phase
Observational
Started
2026-09-20
Last updated
2026-09-18

Condition(s) studied

Peri-Implant Mucositis

Study summary

This study compares two types of dental implants, short implants (6 millimeters or less in length) and standard implants (longer than 8 millimeters), to evaluate their effect on the health of the gum and bone tissue surrounding the implant. Approximately 40 patients receiving a total of 80 dental implants will be followed. Researchers will assess clinical signs of gum health around the implants, measure specific protein levels (biomarkers) in the fluid surrounding the implants associated with gum disease. The goal of this study is to determine whether implant length affects the risk of inflammation or infection around dental implants, which may help guide treatment decisions in the future.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Systemically healthy adults aged 18-70 years. * Presence of at least one short (≤6 mm) and/or standard (\>8 mm) dental implant in function for at least 2 years. * Patients presenting to the Department of Periodontology, Faculty of Dentistry, Inonu University, for routine dental examination. * For the peri-implant health group: absence of clinical signs of inflammation (redness, edema, or suppuration), absence of bleeding on probing (BOP), probing pocket depth (PPD) ≤5 mm, full-mouth BOP \<10%, no radiographic evidence of pathological peri-implant bone loss, and no clinical implant mobility. * For the peri-implant mucositis group: presence of clinical signs of inflammation (redness and/or edema) without suppuration, presence of bleeding on probing (BOP), probing pocket depth (PPD) ≤5 mm, full-mouth BOP \>10%, no radiographic evidence of pathological peri-implant bone loss, and no clinical implant mobility. Exclusion Criteria: * Age younger than 18 years or older than 70 years. * Presence of any systemic disease. * Immune system disorders or use of immunosuppressive medications. * Requirement for antibiotic prophylaxis before dental procedures. * Bisphosphonate therapy for osteoporosis. * Pregnancy or lactation. * Smoking. * Alcohol consumption. * Antibiotic treatment within the previous 6 months. * Continuous use of systemic medications.

Primary outcome measure(s)

  • Change in Peri-Implant Crevicular Fluid RANKL Level — Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
    Receptor activator of nuclear factor kappa-B ligand (RANKL) levels in peri-implant crevicular fluid (PICF) will be measured using enzyme-linked immunosorbent assay (ELISA) and compared between short and standard implant groups.
  • Change in Peri-Implant Crevicular Fluid OPG Level — Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
    Osteoprotegerin (OPG) levels in peri-implant crevicular fluid (PICF) will be measured using enzyme-linked immunosorbent assay (ELISA) and compared between short and standard implant groups.
  • Change in Peri-Implant Crevicular Fluid Cathepsin K Level — Baseline; 1 and 3 months after non-surgical peri-implant therapy in participants who develop peri-implant mucositis.
    Cathepsin K levels in peri-implant crevicular fluid (PICF) will be measured using enzyme-linked immunosorbent assay (ELISA) and compared between short and standard implant groups.

Trial sites (1)

FacilityCityRegionStatus
Inonu University Faculty of Dentistry Malatya Turkey (Türkiye)

More Inonu University trials in Turkey

Effect of Augmented Low-dye* Taping and Exercise on Plantar Pressure, Navicular Drop and Foot Posture in Pes Planus Active, not recruiting
Liver Transplant Recipients and 30-Second Lie-to-Sit Test Recruiting
Blood Parameter Changes Following Aerobic Exercise in Professional Soccer Players Starting soon
The Effect of Web-based Education on Gynecological Cancer Awareness and Healthy Life Behaviors Enrolling by invitation
Nonpharmacological Management of Pain and Fear During Hormone Injection in Breast Cancer Patients Starting soon

Other trials for the same condition

Impact of Keratinized Mucosa Augmentation on Treatment Outcomes of Peri-implant Mucositis Recruiting
Clinical, Radiographic, and Digital Evaluation of the Effects of Autogenous Grafts on Peri-implant Mucosa Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07828067 on ClinicalTrials.gov ↗ ← All trials in Turkey